Hidden GLP‑1 side effects
Researchers using Reddit posts flagged symptoms users say were underreported in trials — fatigue, chills and menstrual irregularities were commonly mentioned. ( ) Meanwhile, some U.S. states are already rolling back Medicaid coverage for GLP‑1 weight‑loss drugs as demand rises. (theguardian.com) Lastly, separate reporting notes that even when users don’t lose much weight, there is emerging evidence of liver and heart benefits for some patients. (wpbf.com)
These drugs were built to mimic a gut hormone that slows digestion and reduces appetite, but a new University of Pennsylvania study found users describing side effects that official trials and labels may have missed. (nature.com) The Penn team used artificial intelligence to analyze more than 400,000 Reddit posts from nearly 70,000 users discussing semaglutide and tirzepatide, the medicines sold as Ozempic, Wegovy, Mounjaro and Zepbound. The study was published April 10 in *Nature Digital Medicine*’s sister journal *Nature Health*. (seas.upenn.edu, nature.com) Gastrointestinal problems still dominated the posts, with nausea mentioned in 36.9% of reports, fatigue in 16.7%, vomiting in 16.3%, constipation in 15.3% and diarrhea in 12.6%. The researchers said menstrual irregularities, chills and hot flashes stood out as “unrecognized potential effects” that were not well captured in labeling or trials. (nature.com) The study did not prove the drugs caused those symptoms. The authors said social media can surface patterns faster than formal trials, but online posts are self-reported, not controlled, and can miss other explanations such as dose changes, other medicines or underlying illness. (nature.com, medicalnewstoday.com) The timing is awkward for patients because access is already tightening. The Guardian reported on April 14 that several states and public plans have rolled back coverage for glucagon-like peptide-1 weight-loss drugs as costs climbed and demand spread beyond diabetes treatment. (theguardian.com) California’s Medicaid program, Medi-Cal, stopped covering these drugs for weight loss alone on January 1, 2026, while still allowing coverage for some non-weight-loss uses with prior authorization. The California Medical Association said the policy applies to both fee-for-service Medi-Cal and managed care plans. (cmadocs.org, medi-calrx.dhcs.ca.gov) At the same time, researchers are reporting that the drugs may help some organs even when the scale barely moves. A Cell Metabolism study published April 14 found semaglutide improved liver function in mice with metabolic dysfunction-associated steatohepatitis through direct signaling in liver blood-vessel cells, not only through weight loss. (cell.com, medicalxpress.com) Heart data have been pointing in a similar direction. A Lancet analysis of the SELECT trial published in October 2025 found semaglutide’s cardiovascular protection was largely independent of baseline body size and weight loss, building on the 2023 New England Journal of Medicine trial that showed fewer heart attacks, strokes and cardiovascular deaths in adults with obesity or overweight and prior cardiovascular disease. (thelancet.com, nejm.org) So the picture around these medicines is getting more complicated, not simpler: new patient-reported symptoms are surfacing just as insurers and Medicaid programs narrow access, even while liver and heart research keeps expanding the list of possible benefits. (nature.com, theguardian.com, thelancet.com)
